Details
Clinical Trials in Retinitis Pigmentosa Treatment
|
CHF 165.50 |
|
| Verlag: | Springer |
| Format: | |
| Veröffentl.: | 20.08.2024 |
| ISBN/EAN: | 9783031587993 |
| Sprache: | englisch |
| Anzahl Seiten: | 350 |
Dieses eBook enthält ein Wasserzeichen.
Beschreibungen
<p>This book is a compendium of the worldwide ocular stem cell, gene therapy, optogenetic, and other miscellaneous studies treating Retinitis Pigmentosa registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study title and the Clinical Trial Number is provided in order to make it easier for the reader to obtain further information. The book contains chapters that act as an introduction to Retinitis Pigmentosa, as well as discussion and analysis of the studies. References are also included for the readers’ use. </p>
<p><em>Clinical Trials in Retinitis Pigmentosa Treatment</em> is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.</p>
<p><em>Clinical Trials in Retinitis Pigmentosa Treatment</em> is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.</p>
<p><strong>Part 1: Introduction</strong>.- Chapter 1. Introduction to Retinitis Pigmentosa.- Chapter 2. Treatments.- Chapter 3. Notes.- <strong>Part 2: Completed Clinical Trials</strong>.- Chapter 4. United States.- Chapter 5. Brazil.- Chapter 6. Turkey.- <strong>Part 3: Active, Recruiting Clinical Trials</strong>.- Chapter 7. United States.- Chapter 8. Latin America.- Chapter 9. Turkey.- <strong>Part 4: Not Yet Recruiting Clinical Trials</strong>.- Chapter 10. Indonesia.- <strong>Part 5: Active, Not Recruiting</strong>.- Chapter 11. United States.- Chapter 12. France.- <strong>Part 6: Enrolling by Invitation</strong>.- Chapter 13. United States.- Chapter 14. Indonesia.- <strong>Part 7: Gene Therapy Studies</strong>.- Chapter 15. United States/Europe.- Chapter 16. India.- Chapter 17. Saudi Arabia.- <strong>Part 8: Active, Recruiting Gene Therapy Studies</strong>.- Chapter 18. United States.- Chapter 19. China.- <strong>Part 9: Active, Not Recruiting Gene Therapy Studies</strong>.- Chapter 20. United States.- Chapter 21. Germany.- Chapter 22. Sweden.- <strong>Part 10: Enrolling by Invitation Gene Therapy Studies</strong>.- Chapter 23. Americas/Europe.- Chapter 24. India.- <strong>Part 11: Optogenetics</strong>.- Chapter 25. Active Trials in United States.- <strong>Part 12: Other Treatments</strong>.- Chapter 26. Completed Trials in The Americas/Europe.- Chapter 27. Completed Trials in China.- Chapter 28. Completed Trials in Italy.- Chapter 29. Completed Trials in Turkey.- Chapter 30. Active Trials in the United States.- Chapter 31. Active Trials in Australia.- Chapter 32. Active Trials in China.- Chapter 33. Active, Not Recruiting Trials in the US/Europe.- Chapter 34. Not Yet Recruiting Trials in China. </p>
<p><strong>Jeffrey N. Weiss, M.D.,</strong> is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology. </p><p><br></p><p>Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss’ inventions worldwide. </p><p><br></p><p>Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment tosuccessfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions. </p><p><br></p><p>Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov. </p>
<p>This book is a compendium of the worldwide ocular stem cell, gene therapy, optogenetic, and other miscellaneous studies treating Retinitis Pigmentosa registered with Clinicaltrials.gov. Clinicaltrials.gov is the largest website listing of registered clinical research studies in the world. The study title and the Clinical Trial Number is provided in order to make it easier for the reader to obtain further information. The book contains chapters that act as an introduction to Retinitis Pigmentosa, as well as discussion and analysis of the studies. References are also included for the readers’ use. </p>
<p><em>Clinical Trials in Retinitis Pigmentosa Treatment</em> is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.</p>
<p><em>Clinical Trials in Retinitis Pigmentosa Treatment</em> is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers.</p>
Offers a comprehensive review of clinical trials in the treatment of Retinitis Pigmentosa The first book to provide coverage on clinical trials in the treatment of Retinitis Pigmentosa Covers active studies as well as completed, withdrawn, and terminated studies
Diese Produkte könnten Sie auch interessieren:
Actualidades en dolor
von: Raúl Carrillo Esper, Raúl Carrillo Editorial Alfil, S. A. de C. V.
CHF 11.00
El ABC de la cirugía plástica 2019. Temas estéticos
von: Ramiro Hesiquio Silva, Manuel Barrantes Tijerina, Manuel Barrantes Editorial Alfil, S. A. de C. V.
CHF 11.00
